Literature DB >> 31743765

There "ain't no mountain high enough"?: The drivers, diversity and sustainability of China's Rhodiola trade.

A B Cunningham1, H L Li2, P Luo2, W J Zhao3, X C Long4, J A Brinckmann5.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Across Asia, Rhodiola species have been used in Bhutanese, Mongolian, Nepalese, Kazakh, Kyrgyz and Uzbek traditional medical systems. China is globally significant in terms of Rhodiola species diversity, with over 60% (55 species) of the world's 90 Rhodiola species, including 16 species found nowhere else in the world. Since the late 1980's there has been a shift from relatively low demand for infusions using chopped dried Rhodiola roots, to high 21st century demand for a wide variety of processed products. China's trade in Rhodiola products is now very diverse, with use in cosmetics and foods in addition to herbal products. Rhodiola crenulata (Hook.f. & Thomson) H.Ohba is the most widely traded species in China. In addition to R. crenulata and Rhodiola rosea L., 19 Rhodiola other species are used. AIMS OF THE STUDY: These were to: (i) better understand why adulteration occurs in Rhodiola products; (ii) become more aware of what drives the growing market demand for Rhodiola products in China; (iii) find out whether increased demand is reflected in wholesale prices for Rhodiola raw materials traditional medicine markets; (iv) to examine Rhodiola supply chains and (v) given that wild populations are the primary supply source, to review the implications of growing demand for conservation and sustainable use.
MATERIALS AND METHODS: Firstly, we assessed growth in the diversity of Rhodiola products using three approaches: (i) by assessing patent applications for Rhodiola products in China (1990-2019); (ii) in 2018, through on-line searches of CFDA (China Food and Drug Administration) records for medicines and dietary supplements that had Rhodiola as an ingredient and (iii) by visiting retail stores in 2018 and 2019 to assess the diversity of commercial Rhodiola based products in trade. Secondly, we visited traditional medicine markets in Yunnan, Sichuan, and Qinghai provinces to investigate the trade in Rhodiola (folk taxonomy, trade names, prices, source areas, levels of processing and grading). Thirdly, we analysed the wholesale price data for Rhodiola raw materials in trade over a 16-year period (2002-2018). Fourthly, as most products come from wild collected Rhodiola species, we documented the extent of Rhodiola cultivation in China.
RESULTS: International exports of Rhodiola products from China, particularly extracts, is a major driver of commercial trade. One proxy indicator of Rhodiola product diversification in China has been the rapid rise in patent applications from single applications in 1990 and 1991, to a peak of 1017 patent applications in 2015. Wholesale price data from 2002 to 2018 shows a steady increase in wholesale prices. As the growing market for Rhodiola products in China is currently supplied entirely from wild collection, there are justifiable concerns about sustainability. Commercial cultivation needs to expand to meet future demand.
CONCLUSIONS: In contrast to Europe and North America, where R. rosea is the focal species in commerce, the trade in Rhodiola products in China is much more diverse. In the face of growing demand, both effective conservation of wild populations and cultivation are needed.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adulteration; Folk taxonomy; Market prices; Sustainability; Traceability

Year:  2019        PMID: 31743765     DOI: 10.1016/j.jep.2019.112379

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  5 in total

1.  Application of UHPLC Fingerprints Combined with Chemical Pattern Recognition Analysis in the Differentiation of Six Rhodiola Species.

Authors:  Didi Ma; Lijun Wang; Yibao Jin; Lifei Gu; Xiean Yu; Xueqing Xie; Guo Yin; Jue Wang; Kaishun Bi; Yi Lu; Tiejie Wang
Journal:  Molecules       Date:  2021-11-13       Impact factor: 4.411

Review 2.  Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases.

Authors:  Jingxuan Han; Lailiu Luo; Yicheng Wang; Shourong Wu; Vivi Kasim
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

Review 3.  Quality Evaluation of Randomized Controlled Trials of Rhodiola Species: A Systematic Review.

Authors:  Xiuzhu Li; Weijie Chen; Yingqi Xu; Zuanji Liang; Hao Hu; Shengpeng Wang; Yitao Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-01       Impact factor: 2.629

Review 4.  West meets east: open up a dialogue on phytomedicine.

Authors:  Xiuzhu Li; Weijie Chen; Jesus Simal-Gandara; Milen I Georgiev; Hongyi Li; Hao Hu; Xu Wu; Thomas Efferth; Shengpeng Wang
Journal:  Chin Med       Date:  2021-07-19       Impact factor: 5.455

5.  Phytochemical, Antibacterial and Antioxidant Activity Evaluation of Rhodiola crenulata.

Authors:  Lingyun Zhong; Lianxin Peng; Jia Fu; Liang Zou; Gang Zhao; Jianglin Zhao
Journal:  Molecules       Date:  2020-08-12       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.